AzTrials
AzTrials

Knee OsteoarthritisNCT06567301

Extracorporeal Shockwave Versus Phonophoresis Using Chitosan-Nanoparticles Gel on Functional and Anatomical Changes Detected With Artificial Intelligence Based Texture Analysis Algorithm in Knee Osteoarthritis Patients: A Double Blind Randomized Controlled Trial

A study testing Ultrasound therapy combined with Chitosan nanoparticles gel in people with Knee Osteoarthritis and Chitosan Nanoparticles Gel, run by Cairo University at 2 sites in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

A parallel double blinded randomized controlled clinical trial (RCT) with a 1:1:1 allocation will be conducted in an orthopedic clinic in Cairo and Giza Governments - Egypt. This RCT will evaluate the pain reduction, self-reported functional improvement, physical functional and anatomical improvement following the… Read more about this study

Who is it for?
Ages 40 to 60 years
What is being tested?
Ultrasound therapy combined with Chitosan nanoparticles gel
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
120 participants
Where
2 sitesEgypt
Study dates
25 Oct 2023to 30 Jun 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Age between ≥40 and ≤ 65 years old.
  • Both genders.
  • Patients should have OA of the knee, Kellgren-Lawrence scores of 2 and 3 on radiologic evaluation.
  • If both knees diagnosed as OA, the most affected one will be selected.
  • Diagnosis of KOA who had knee pain and functional disabilities for at least three months, according to American College of Rheumatology classification (ACR) at screening visit.
  • Visual Analogue Scale (VAS) at rest score of ≥40 mm.
  • Subjects have sufficient cognition that enables them to understand the requirements of the study, comply with the study procedures and visit schedule.

Who cannot join

  • Patients with any previous knee surgeries or lower limb fractures.
  • Chronic inflammatory diseases such as rheumatoid arthritis.
  • Any neurological disorders.
  • Moderate to significant knee synovitis.
  • Hot or red knee.
  • History and/or physical examination findings compatible with the internal derangement of knee.
Show all 16Show fewer
  • Pregnancy.
  • Patients with BMI more than 35 (morbid obesity).
  • Absence of current physical therapy treatments for KOA.
  • Cognitive limitations or endocrine disease.
  • Patients who had undergone arthroscopy or treatment with intra-articular hyaluronic acid during previous 6 months.
  • Use of NSAIDs one week prior to screening visit.
  • Orthopedic diseases that may affect or interfere with the therapeutic effect.
  • Habitual use of psychotropic or narcotic analgesics for ≥1 week within 8 weeks prior to screening.
  • Participated in other intervention studies on the past 6 months to screening
  • Participants with congenital musculoskeletal deformity.

Trial locations and contacts

2 sites in 1 country.

Athar Tarek Mohamed Fahmy Azab, Master contact

0201001909236

athartarek29790@gmail.com

Hamdy Mamdouh Amir contact

0201112831021

athartarek29790@gmail.com

Egypt2 sites, 2 recruiting
  • Physical Therapy College - Cairo University

    Giza, El Dokki, 12613

    Recruiting
  • Physical therapy college - Cairo University

    Giza, EL Doqqi, 12613

    Recruiting

Other trials in Egypt

About this study

Official title: Extracorporeal Shockwave Versus Phonophoresis on Functional and Anatomical Changes Detected With Artificial Intelligence Technology in Knee Osteoarthritis

A parallel double blinded randomized controlled clinical trial (RCT) with a 1:1:1 allocation will be conducted in an orthopedic clinic in Cairo and Giza Governments - Egypt.

This RCT will evaluate the pain reduction, self-reported functional improvement, physical functional and anatomical improvement following the application of phonophoresis using chitosan-nanoparticles gel, ECSW therapy and traditional exercises compared to each other.

The treatment period will last for 4 weeks with a total of (12 sessions/ 3 sessions per week for the application of phonophoresis using chitosan-nanoparticles gel and traditional exercises program) and (5 sessions/ 1 every week for the application of ECSWT). The participants will be assessed at two different time-points (before-after treatment) with a sample size of 40 patients in each group (3 groups)

Read the detailed description

Osteoarthritis (OA) is a common degenerative disease that is ranked as the 10th largest contributor to disabilities that has a link to higher comorbidity and excess mortality. One of most common degenerative diseases is knee osteoarthritis (KOA). KOA is a progressive, chronic degenerative condition that places a heavy socioeconomic burden on healthcare systems and society. The prevalence of knee OA has sharply increased to more than the double in the last 10 years as result of steady state in life expectancy.

KOA is a well-known as a cartilage disease that involves degradation and loss of articular cartilage. However, OA is usually accompanied by changes in the subchondral bone, with sclerosis, bone cyst, and osteophyte formation.

Recent studies reported that subchondral bone remodeling plays a very important role in KOA, mediating and preceding cartilage damage. The increase in subchondral bone stiffness decreases the ability to scatter the loading forces within the knee joint, which then increases the force loaded on articular cartilage. Therefore, the cartilage damage and progress of OA accelerated over time. The focus of treatment in early KOA have shifted from the articular cartilage to the subchondral bone and become a potential therapeutic target of various therapeutic methods.

Regarding KOA pain, accumulating evidence suggests that bottom-up vascularization from subchondral bone plays a larger role than top-down vessel invasion originating from synovial tissue or synovium during cartilage erosion in OA. As a result, it is a common complaint of orthopedists that osteoarthritis pain is not associated with the radiographic presentation. Recent work revealed a relatively weak relationship between cartilage loss and OA joint pain.

As different approaches aimed at articular cartilage or synovial components had inefficient results and the mechanism of bone cartilage crosstalk is gradually becoming clear, this study will try to confirm the critical role of subchondral bone in knee osteoarthritis and that subchondral bone could be an ideal outcome measure of osteoarthritis treatment.

Low-intensity pulsed ultrasound (LIPUS) and extracorporeal shockwave therapy (ECSWT) are effective as a non-invasive method in histopathological recovery with more intense sight, ECSWT has shown effectiveness in the regression of early KOA associated with improving the subchondral bone remodeling, decrease the number of osteophytes and it can also increase osteocytes activity. Besides, ECSWT could alleviate chronic inflammatory activities in the whole joint through down-regulating inflammatory cytokines. Additionally, it was reported that application of ESWT to the subchondral bone of the knee significantly increased bone volume and trabecular number and reduced bone porosity. Overall, ESWT could reverse the pathology of OA progression to some extent.

Low-intensity US might influence the subchondral bone unit under joint disuse. LIUS with its associated acoustic radiation force can alleviate subchondral bone sclerosis during OA progression under normal joint use. In addition, if US technology combined with bioactive compounds materials as chitosan (CS), could improve the encapsulation efficiency of bioactive compounds whereas not only reduced the nanoparticle size but also narrowed their size distribution, this makes US as an effective delivery of biomaterials such as chitosan. In this context, inclusion of mixed interventions with US could improve its effect. Therefore, this study will couple the use of US therapy with a new green environmentally friendly material called chitosan in the form of a topical gel.

Chitosan appears as proteoglycan in the extracellular matrix (shells) of some species of cephalopods. Chitosan's biocompatibility, gradual degradability, non-toxicity, biological activity, anti-inflammatory properties, and antibacterial action, makes chitosan regarded as the best material for hydrogel. Some studies used CS as intra-articular injection for KOA and concluded that CS can promote chondrocyte proliferation, block inflammatory and catabolic mediators. Therefore, Phonophoresis using chitosan could reduce inflammation, limit cartilage degeneration and improve subchondral bone remodeling process.

Additionally, it is well known that confirming diagnosis of KOA is based on assessing joint space width and this is carried out through radiography which depends on the Kellgren-Lawrence grade (K-LG) scale. Despite K-LG scale is considered the most used classical diagnostic tool for KO, it has several drawbacks, including its application to the progression of diseases, its insensitivity to change, or inconsistencies in the authors' initial descriptions. Furthermore, it is limited in how it evaluates treatment efficacy because it mostly uses pain scores.

By looking to the adverse effects of conventional radiology, many studies had reported the possibility of an allergic reaction, expensive costs, lengthy inspection times, and difficulties in scanning patients with specific conditions.

Taking this into account, artificial intelligence (AI)-based approaches are starting to be used to solve these issues as image identification, pre-operative risk assessment, clinical decision- making, and analysis of large data sets, diagnosis, monitor, prognosis of rheumatological diseases, identifying risk factors for complications and has the unique ability to anticipate outcomes using patient-specific algorithms. AI plays a vital role in the appraisal of treatment, in which key progress in the clinical practice of rheumatology is the innovation of advanced imaging modalities.

The use of AI in orthopedics has mostly concentrated on the development of Machine learning (ML) and deep learning (DL) on these pictures. Deep learning, which is a subset of ML, can assist in automatic interpretation of medical images, which may increase diagnostic accuracy and speed, flag the most urgent and critical patients for immediate attention, reduce the amount of human error caused by fatigue and/or inexperience, lessen the strain on medical professionals by reducing their workload, and, in general, improve orthopedic care.

Subchondral bone-remodeling process was reported previously as an important pathophysiology of KO whereas subchondral bone sclerosis is widely considered to be the hallmark of OA. Texture analysis (TA) algorithm is used to detect changes in the subchondral bone density during remodeling process. It was demonstrated encouraging findings and the potential of automated texture analysis employing an AI algorithm as a diagnostic tool for OA in comparison to traditional TA techniques. Bone structure value (BSV) is considered as a maximum-likelihood estimator of OA as automated TA depends on it in the analysis and assessment process that measures the micro-structure of the tibial subchondral bone depends on area of interest (ROI). Consequently, the purpose of this study is to explore the difference between ECSWT, LIUS and traditional exercises regarding the pain reduction, functional improvement (self-reported and physical function) and anatomical improvement of subchondral bone (trabecular tibial bone) micro-structural changes.

Being tested
Ultrasound therapy combined with Chitosan nanoparticles gel
Keywords
knee osteoarthritis, chitosan nanoparticles gel, artificial intelligence, texture analysis, artificial intelligence texture analysis bases algorithm, chitosan, subchondral bone changes, anatomical changes, Extracorporeal shockwave, ultrasound therapy, Phonophoresis, medical imaging, knee OA pathogenesis, pathophysiology
Medical subject headings
Osteoarthritis, Knee

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ultrasound therapy combined with Chitosan nanoparticles gelCombination product

    Also called Extracorporeal Shockwave Therapy

    Gymna - Belgian

Study groups in NCT06567301
Study groupRoleWhat they receive
Group A: Ultrasound therapy combined with Chitosan nanoparticles gel and Exercises ProgramExperimentalIn this group will receive ultrasound therapy coupled with chitosan-nanoparticles gel with an exercises program. The US protocol which will consist of pulsed ultrasound waves. The parameters that will be selected consists of; frequency of 1 MHz, 1 W/cm2 power delivered at an intensity of an intensity of 2.5W/ cm2 and with duty cycle of 25% and will be applied with a 5-cm diameter applicator. The area of treatment will be cleaned to permit an effective skin applicator coupling. Each patient will be placed in a supine position for the application of ultrasound. A suitable palpation to locate the discomfort source and some passive motions to identify a range of motion restriction will be completed prior to the ultrasound application. Ultrasound will be applied to the medial and lateral aspects of the knee in circular motions, with the probe at right angles to ensure maximum absorption of energy. Each session will last for 5 minutes.
Receives: Combination Product: Ultrasound therapy combined with Chitosan nanoparticles gel
Group B: Application of Extracorporeal Shockwave and Exercises Program:Active comparatorThis group will receive ESWT with an exercises program. Subjects will receive 5 sessions, one week apart. Before the treatment, subjects will be placed in supine to expose and prepare the treated area with the knee flexed at angle of 90° and the hip is abducted and externally rotated. The impulses will be applied on the subchondral bone at the medial and lateral tibia condyle at 2.0 cm below the joint line in anteroposterior view and 2.0 cm from the medial skin edge in lateral view. The treatment application will be as follows: 2000 impulses will be administered at (EFD) with an energy flux density ranging from 0.22-0.43 mJ / mm2 at 8 Hz. In which 0.22 mJ/mm²: likely corresponds to around 1.5-3 bars, while 0.43 mJ/mm² likely corresponds to around 3-5 bars. The probe was chosen effective treatment depth (5-20-mm focal depth), semi-movable technique of the shockwave applicator and 5 minutes duration.
Receives: Combination Product: Ultrasound therapy combined with Chitosan nanoparticles gel
Group C: Exercises ProgramPlacebo comparatorPatients in this group will receive only an exercises program for 3 times weekly for 4 weeks. This program includes: (1) Warming-up (5 min); (2) strengthening exercises for the lower limbs: 3 sets of 15 repetitions: flexion SLR, abduction SLR, and extension SLR, standing knee flexion, quadriceps isometrics, 10 repetitions of 5 s, 0° and 30°; (3) aerobic exercise on a stationary bike (20 min), (4) and stretching (5 min) with a weekend break. All patients in the three groups (A, B and C) will receive the same exercise program.
Receives: Combination Product: Ultrasound therapy combined with Chitosan nanoparticles gel

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Anatomical improvement

    subchondral bone improvement following the application of Phonophoresis using chitosan-nanoparticles gel, ECSW therapy and assessed by Artificial intelligence based texture analysis algorithm

    Measured: one month

Secondary outcomes (1)
  1. level of knee pain

    by VAS

    Measured: one month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Aug 2024
  2. Study start25 Oct 2023
  3. Primary completion30 May 2025 (estimated)
  4. Study completion30 Jun 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Single group
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06567301
Sponsor's protocol ID
P.T.REC/012/005026
Status last verified
Aug 2024
First submitted
20 Aug 2024
Last updated
26 Aug 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Ultrasound therapy combined with Chitosan nanoparticles gel in people with Knee Osteoarthritis and Chitosan Nanoparticles Gel, run by Cairo University at 2 sites in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 26 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Athar Tarek Mohamed Fahmy Azab, Master (0201001909236, athartarek29790@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Anatomical improvement (time frame: one month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in